353 related articles for article (PubMed ID: 16019857)
1. The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Masunaga S; Nagasawa H; Uto Y; Hori H; Suzuki M; Nagata K; Kinashi Y; Ono K
Int J Hyperthermia; 2005 Jun; 21(4):305-18. PubMed ID: 16019857
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
Masunaga S; Ono K; Hori H; Akaboshi M; Kawai K; Suzuki M; Kinashi Y; Kasai S; Nagasawa H; Uto Y
Radiat Med; 1998; 16(6):441-8. PubMed ID: 9929144
[TBL] [Abstract][Full Text] [Related]
3. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia in γ-ray irradiation in terms of local tumour response and lung metastatic potential.
Masunaga S; Liu Y; Sakurai Y; Tanaka H; Suzuki M; Kondo N; Maruhashi A; Ono K
Int J Hyperthermia; 2012; 28(7):636-44. PubMed ID: 22946564
[TBL] [Abstract][Full Text] [Related]
5. The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
Masunaga S; Nagasawa H; Sakurai Y; Uto Y; Hori H; Nagata K; Suzuki M; Maruhashi A; Kinashi Y; Ono K
Int J Hyperthermia; 2006 Jun; 22(4):287-99. PubMed ID: 16754350
[TBL] [Abstract][Full Text] [Related]
6. Effects of mild temperature hyperthermia and p53 status on the size of hypoxic fractions in solid tumors, with reference to the effect in intratumor quiescent cell populations.
Masunaga S; Takahashi A; Ohnishi K; Ohnishi T; Nagata K; Suzuki M; Kinashi Y; Ono K
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):570-7. PubMed ID: 15380594
[TBL] [Abstract][Full Text] [Related]
7. Potentially lethal damage repair by total and quiescent tumor cells following various DNA-damaging treatments.
Masunaga S; Ono K; Hori H; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y
Radiat Med; 1999; 17(4):259-64. PubMed ID: 10510897
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of a continuous administration of tirapazamine combined with reduced dose-rate irradiation using {gamma}-rays or reactor thermal neutrons.
Masunaga S; Sakurai Y; Nagata K; Suzuki M; Maruhashi A; Kinashi Y; Nagasawa H; Uto Y; Hori H; Ono K
Br J Radiol; 2006 Dec; 79(948):991-8. PubMed ID: 16916808
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.
Masunaga S; Ono K; Takahashi A; Ohnishi K; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Nagasawa H; Uto Y; Hori H
Cancer Sci; 2003 Jan; 94(1):125-33. PubMed ID: 12708486
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
Masunaga S; Ono K; Nishimura Y; Kanamori S; Saga T; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):799-807. PubMed ID: 10837967
[TBL] [Abstract][Full Text] [Related]
12. Change in oxygenation status in intratumour total and quiescent cells following gamma-ray irradiation, tirapazamine administration, cisplatin injection and bleomycin treatment.
Masunaga S; Ono K; Hori H; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y
Br J Radiol; 2000 Sep; 73(873):978-86. PubMed ID: 11064652
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: reference to the effect on intratumor quiescent cells.
Masunaga SI; Ono K; Suzuki M; Kinashi Y; Takagaki M; Hori H; Kasai S; Nagasawa H; Uto Y
Jpn J Cancer Res; 2000 May; 91(5):566-72. PubMed ID: 10835503
[TBL] [Abstract][Full Text] [Related]
14. Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells.
Masunaga S; Ono K; Hori H; Kinashi Y; Suzuki M; Takagaki M; Kasai S; Nagasawa H; Uto Y
Int J Hyperthermia; 1999; 15(1):7-16. PubMed ID: 10193753
[TBL] [Abstract][Full Text] [Related]
15. Determination and drug modification assessed by micronucleus frequency assay of potentially lethal damage repair in quiescent cell populations within murine solid tumors.
Masunaga S; Ono K; Akaboshi M; Takagaki M; Kinashi Y; Suzuki M; Abe M
Radiat Med; 1997; 15(1):37-43. PubMed ID: 9134583
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of combination with both continuous administration of hypoxic cytotoxin and mild temperature hyperthermia in boron neutron capture therapy in terms of local tumor response and lung metastatic potential.
Masunaga SI; Sakurai Y; Tanaka H; Takata T; Suzuki M; Sanada Y; Tano K; Maruhashi A; Ono K
Int J Radiat Biol; 2019 Dec; 95(12):1708-1717. PubMed ID: 31545117
[No Abstract] [Full Text] [Related]
17. The usefulness of mild temperature hyperthermia combined with continuous tirapazamine administration under reduced dose-rate irradiation with gamma-rays.
Masunaga S; Nagasawa H; Uto Y; Hori H; Nagata K; Suzuki M; Kashino G; Kinashi Y; Ono K
Int J Hyperthermia; 2007 Feb; 23(1):29-35. PubMed ID: 17575721
[TBL] [Abstract][Full Text] [Related]
18. Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate, TX-2060, as a 10B-carrier in boron neutron capture therapy.
Masunaga S; Nagasawa H; Hiraoka M; Sakurai Y; Uto Y; Hori H; Nagata K; Suzuki M; Maruhashi A; Kinashi Y; Ono K
Anticancer Res; 2004; 24(5A):2975-83. PubMed ID: 15517904
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the potential of p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, referring to the effect on intratumor quiescent cells.
Masunaga SI; Ono K; Kirihata M; Takagaki M; Sakurai Y; Kinashi Y; Kobayashi T; Nagasawa H; Uto Y; Hori H
Jpn J Cancer Res; 2001 Sep; 92(9):996-1007. PubMed ID: 11572769
[TBL] [Abstract][Full Text] [Related]
20. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
Masunaga S; Sakurai Y; Suzuki M; Nagata K; Maruhashi A; Kinash Y; Ono K
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):920-7. PubMed ID: 15465210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
